Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
about
Prognostic value of histone chaperone FACT subunits expression in breast cancer.Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine.14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression.Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.Chemoresistance in pancreatic cancer: Emerging conceptsStabilization of Nucleosomes by Histone Tails and by FACT Revealed by spFRET Microscopy.Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical ModelsPreclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas.Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene.Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins
P2860
Q33649913-4D9DCDFC-BE27-4A6D-9A88-085DEDA5C91CQ36946804-13623CA1-1E07-48A3-AEFB-D78F7896AF7EQ37109577-42A8A80C-418F-4FF3-AB92-A0C476AD193AQ38744639-A2CB0889-D2FB-4340-BC1A-0EC8DA0CD579Q42002078-25A4B1B0-BE01-410B-BC1A-D75A00BC6800Q42138478-46C6A5F8-1CEB-4CEB-8F4D-48AA2889C322Q42359768-C7358001-23C3-4D69-B58F-8206B55F9532Q42775850-C5AC3A73-20DC-4418-83A0-A565FB2EA5F4Q43376660-41A40B63-74B7-4650-98F5-1D96823385C1Q48644134-9F29BE3D-A4A1-4162-B2A5-2BE1817FA14FQ55497983-DE91D44D-A5BC-494B-8ED8-805D5330914AQ58699740-D26969ED-F321-49CE-B8E2-ED3107E30122
P2860
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Curaxin CBL0137 eradicates dru ...... l models of pancreatic cancer.
@ast
Curaxin CBL0137 eradicates dru ...... l models of pancreatic cancer.
@en
Curaxin CBL0137 eradicates dru ...... l models of pancreatic cancer.
@nl
type
label
Curaxin CBL0137 eradicates dru ...... l models of pancreatic cancer.
@ast
Curaxin CBL0137 eradicates dru ...... l models of pancreatic cancer.
@en
Curaxin CBL0137 eradicates dru ...... l models of pancreatic cancer.
@nl
prefLabel
Curaxin CBL0137 eradicates dru ...... l models of pancreatic cancer.
@ast
Curaxin CBL0137 eradicates dru ...... l models of pancreatic cancer.
@en
Curaxin CBL0137 eradicates dru ...... l models of pancreatic cancer.
@nl
P2093
P2860
P356
P1433
P1476
Curaxin CBL0137 eradicates dru ...... l models of pancreatic cancer.
@en
P2093
Catherine Burkhart
Daria Fleyshman
Ilya Toshkov
Jennifer Garrigan
Katerina V Gurova
Laura Martello
Mairead Commane
Rachael Kohrn
Rajesh Ramachandran
Vadim Kurbatov
P2860
P304
11038-11053
P356
10.18632/ONCOTARGET.2701
P407
P577
2014-11-01T00:00:00Z